4-hydoxy-1-(3-pyridyl)-1-butanone: structure given in first source; may be metabolic product of tobacco-specific nitrosamines
ID Source | ID |
---|---|
PubMed CID | 107819 |
CHEMBL ID | 17416 |
CHEBI ID | 82563 |
SCHEMBL ID | 2945748 |
MeSH ID | M0200266 |
Synonym |
---|
59578-62-0 |
4-hydroxy-1-(3-pyridyl)-1-butanone |
4-hpb |
chebi:82563 , |
CHEMBL17416 |
KTXUGZHJVRHQGP-UHFFFAOYSA-N |
4-(3-pyridyl)-4-oxobutanol |
4-hydroxy-1-pyridin-3-ylbutan-1-one |
AKOS006278678 |
C19565 |
4-hydroxy-1-(3-pyridinyl)-1-butanone |
FT-0670076 |
FT-0670074 |
FT-0670075 |
4-hydoxy-1-(3-pyridyl)-1-butanone |
z79cgy64xc , |
1-butanone, 4-hydroxy-1-(3-pyridinyl)- |
unii-z79cgy64xc |
SCHEMBL2945748 |
DTXSID40208240 |
AS-61914 |
W11994 |
4-hydroxy-1-(pyridin-3-yl)butan-1-one |
Q27156077 |
mfcd01320411 |
4-hydroxy-1-(3-pyridyl)-1-butanone (hpb) |
SB84868 |
CS-0315776 |
Class | Description |
---|---|
aromatic ketone | A ketone in which the carbonyl group is attached to an aromatic ring. |
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res] |
Assay ID | Title | Year | Journal | Article |
---|---|---|---|---|
AID22924 | Rate of formation of compound by F-344 rat liver microsomes | 1980 | Journal of medicinal chemistry, Nov, Volume: 23, Issue:11 | Metabolic beta-hydroxylation and N-oxidation of N'-nitrosonornicotine. |
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023] |
Timeframe | Studies, This Drug (%) | All Drugs % |
---|---|---|
pre-1990 | 1 (4.55) | 18.7374 |
1990's | 7 (31.82) | 18.2507 |
2000's | 10 (45.45) | 29.6817 |
2010's | 4 (18.18) | 24.3611 |
2020's | 0 (0.00) | 2.80 |
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] |
Publication Type | This drug (%) | All Drugs (%) |
---|---|---|
Trials | 0 (0.00%) | 5.53% |
Reviews | 1 (4.35%) | 6.00% |
Case Studies | 0 (0.00%) | 4.05% |
Observational | 0 (0.00%) | 0.25% |
Other | 22 (95.65%) | 84.16% |
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] |